Another phase III study, SASCIA, assesses the therapeutic effect of SG in primary HER2 negative breast cancer patients (HR + or TNBC) with high relapse risk after standard neoadjuvant treatment (NCT04595565). This evidence concerns the gene ERBB2 and breast cancer.